Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes of drugs in recent years and are approved for the treatment of a wide range of indications, from cancer to autoimmune disease.
The main areas of focus in therapeutic mAb design are high target specificity, better systemic retention, and low immunogenicity, which can be achieved by antibody engineering technologies. Some of these engineered Ab formats such as chimeric mAbs, humanized mAbs, and fully human mAbs are currently in clinical use, which have the best manufacturability for diagnostic and therapeutic applications, overcoming the potential problems of antibody drug development.